Neuromuscular Disorders
Volume 20, Issue 2 , Pages 142-147 , February 2010

Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008

  • D. Hilton-Jones

      Affiliations

    • Oxford MDC Muscle and Nerve Centre, West Wing, John Radcliffe Hospital, Oxford, UK
    • MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London WC1N3BG, UK
    • ,
  • A. Miller

      Affiliations

    • MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London WC1N3BG, UK
    • ,
  • M. Parton

      Affiliations

    • MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London WC1N3BG, UK
    • ,
  • J. Holton

      Affiliations

    • MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London WC1N3BG, UK
    • ,
  • C. Sewry

      Affiliations

    • MRC Centre for Neuromuscular Disease, UCL Institute of Child Health and Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London, UK
    • ,
  • M.G. Hanna

      Affiliations

    • MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London WC1N3BG, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 0207 837 3611.

Received 2 November 2009

References 

  1. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561–567
  2. Adams R, Kakulas BA, Samaha FAA. A myopathy with cellular inclusions. Trans Am Neurol Assoc. 1965;90:213
  3. Dalakas MC. Sporadic inclusion body myositis – diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006;2:437–447
  4. Cahin N, Engel AG. Correlation of muscle biopsy, clinical course and outcome in PM and sporadic IBM. Neurology. 2008;70:418–424
  5. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705–713
  6. Needham M, Mastaglia FL. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord. 2008;18:6–16
  7. Kula RW, Sawchak JA, Sher JH. Inclusion body myositis. Curr Opin Rheumatol. 1989;1:460–467
  8. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–982
  9. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40:581–586
  10. Dalakas MC, et al. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol. 2007;61(5):466–475
  11. Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA. 1996;93:1314–1319
  12. Bence Neil F. Impairment of the ubiquitin–proteasome system by protein aggregation. Science. 2001;292:1552
  13. Sugarman MC, Yamasaki TR, Oddo S, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci USA. 2002;99:6334–6339
  14. Sugarman MC, Kitazawa M, Baker M, Caiozzo VJ, Querfurth HW, LaFerla FM. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging. 2006;27:423–432
  15. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain. 2008;131:1228–1240
  16. Kiernan D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a co-inducer of heat shock proteins, delays progression in ALS mice. Nat Med. 2004;10:402–405
  17. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;43:876–879
  18. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology. 1994;44:1516–1518
  19. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323–327
  20. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–716
  21. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22–28
  22. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58:326
  23. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566–70.
  24. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63:718–20.
  25. Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002;51:369–372
  26. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58:1081–1087
  27. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore). 1993;72:225–235
  28. Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve. 1997;20:1242–1248
  29. Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med. 2003;35:31–35
  30. Garlepp MJ, Laing B, Zilko PJ, et al. HLA associations with inclusion body myositis. Clin Exp Immunol. 1994;98:40–45
  31. Lampe JB, Gossrau G, Kempe A, et al. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol. 2003;250:1313–1317
  32. Price P, Santoso L, Mastaglia F, et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens. 2004;64:575–580
  33. Badrising UA, Schreuder GM, Giphart MJ, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology. 2004;63:2396–2398
  34. Kok CC, Croager EJ, Witt CS, et al. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Immunogenetics. 1999;49:508–516
  35. Krause S, Schlotter-Weigel B, Walter MC, et al. A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation. Neuromuscul Disord. 2003;13(10):830–834
  36. Krause S, Aleo A, Hinderlich S, et al. GNE protein expression and subcellular distribution are unaltered in HIBM. Neurology. 2007;69(7):655–659
  37. Janiesch PC, Kim J, Mouysset J, et al. The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly to human myopathy. Nat Cell Biol. 2007;9(4):379–390
  38. Hübbers CU, Clemen CS, Kesper K, et al. Pathological consequences of VCP mutations on human striated muscle. Brain. 2007;130(Pt. 2):381–393

PII: S0960-8966(09)00685-3

doi: 10.1016/j.nmd.2009.11.003

Neuromuscular Disorders
Volume 20, Issue 2 , Pages 142-147 , February 2010

Article Tools